About HaploX Biotechnology

HaploX Biotechnology provides full-cycle genetic testing solutions utilizing the LIUDUS® molecular diagnostic technology platform, which includes next-generation sequencing (NGS) and liquid biopsy methods. The company offers precise genetic testing for cancer diagnostics, health risk assessments, and pathogenic microbe detection, enabling informed health management decisions.

```xml <problem> Current genetic testing methods often require multiple platforms and specialized expertise, creating inefficiencies in diagnostics and personalized medicine. Analyzing complex genetic data from various sources can be time-consuming and costly, hindering timely clinical decision-making. </problem> <solution> HaploX Biotechnology offers comprehensive genetic testing solutions through its LIUDUS® molecular diagnostic technology platform, integrating next-generation sequencing (NGS), liquid biopsy, and bioinformatics. The platform provides end-to-end services, from sample processing to data analysis, for cancer diagnostics, health risk assessments, and pathogenic microbe detection. HaploX's testing services deliver actionable insights to support informed health management decisions, covering various tumor types, disease stages, and population groups. The company's laboratories hold certifications from CAP, CLIA, and EMQN, ensuring adherence to global standards for genetic testing. </solution> <features> - LIUDUS® Platform: A low-input, ultra-deep, and ultra-sensitive molecular diagnostic technology platform. - HapOnco® Series: NGS assays for pan-cancer genetic testing, including WESPlus®, StarPanel™, IO Safety, and PARPrion HRD tests. - HapOnco® mClear/mClean MRD Tests: Assays for minimal residual disease (MRD) detection. - HapOnco® CorePanel™/BasicPanel™ NGS Assays: Specific-cancer genetic testing assays. - HapOnco® LungCDx EGFR/ALK NGS Testing Kit: IVD product for non-small cell lung cancer. - TruthGen Panorama/ZenGen Professional Genetic Tests: Solutions for comprehensive health risk assessment. - Specialized Genetic Tests: HeartCipher, VessCipher, OncoCipher, PregCipher, GrowthCipher, ImmuCipher, and AlcohFact Genetic Tests. - Nucleic Acid Extraction Reagents: Magnetic bead method reagents for cfDNA and gDNA extraction from various sample types. </features> <target_audience> The primary audience includes healthcare providers, oncologists, and clinical researchers seeking advanced genetic testing for cancer diagnostics, personalized medicine, and health risk assessment. </target_audience> ```

What does HaploX Biotechnology do?

Where is HaploX Biotechnology located?

HaploX Biotechnology is based in Shenzhen, China.

When was HaploX Biotechnology founded?

HaploX Biotechnology was founded in 2014.

Location

Shenzhen, China

Founded

2014

Employees

14 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

HaploX Biotechnology

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

haplox.com 300+

Founded 2014 – Shenzhen, China

Funding

No funding information available.

Team (10+)

No team information available.

Company Description

Problem

Current genetic testing methods often require multiple platforms and specialized expertise, creating inefficiencies in diagnostics and personalized medicine. Analyzing complex genetic data from various sources can be time-consuming and costly, hindering timely clinical decision-making.

Solution

HaploX Biotechnology offers comprehensive genetic testing solutions through its LIUDUS® molecular diagnostic technology platform, integrating next-generation sequencing (NGS), liquid biopsy, and bioinformatics. The platform provides end-to-end services, from sample processing to data analysis, for cancer diagnostics, health risk assessments, and pathogenic microbe detection. HaploX's testing services deliver actionable insights to support informed health management decisions, covering various tumor types, disease stages, and population groups. The company's laboratories hold certifications from CAP, CLIA, and EMQN, ensuring adherence to global standards for genetic testing.

Features

LIUDUS® Platform: A low-input, ultra-deep, and ultra-sensitive molecular diagnostic technology platform.

HapOnco® Series: NGS assays for pan-cancer genetic testing, including WESPlus®, StarPanel™, IO Safety, and PARPrion HRD tests.

HapOnco® mClear/mClean MRD Tests: Assays for minimal residual disease (MRD) detection.

HapOnco® CorePanel™/BasicPanel™ NGS Assays: Specific-cancer genetic testing assays.

HapOnco® LungCDx EGFR/ALK NGS Testing Kit: IVD product for non-small cell lung cancer.

TruthGen Panorama/ZenGen Professional Genetic Tests: Solutions for comprehensive health risk assessment.

Specialized Genetic Tests: HeartCipher, VessCipher, OncoCipher, PregCipher, GrowthCipher, ImmuCipher, and AlcohFact Genetic Tests.

Nucleic Acid Extraction Reagents: Magnetic bead method reagents for cfDNA and gDNA extraction from various sample types.

Target Audience

The primary audience includes healthcare providers, oncologists, and clinical researchers seeking advanced genetic testing for cancer diagnostics, personalized medicine, and health risk assessment.